《港股》恆指半日跌47點 中芯及華虹走強 香港寬頻飆54%
美聯儲減息四分一厘符預期,匯豐下調港元最優惠利率12.5點子至5.125%。港股早市反覆偏軟,恆指低開44點,曾升149點見27,058點四年高,亦曾跌110點見26,797點。半日跌47點或0.2%,報26,860點;國指跌10點或0.1%,報9,586點;恆生科技指數升65點或1%,報6,400點。大市半日成交總額2,047.14億元。
華為自研昇騰950PR晶片明年首季推出,採用自研HBM記憶體,晶片股繼續急升,中芯(00981.HK)及華虹(01347.HK)升6.6%及10.2%。晶片設備股ASMPT(00522.HK)亦升10.7%。開發人工智能晶片的百度(09888.HK)續炒高4.1%報136.4元,阿里(09988.HK)亦升0.6%報162.5元。雲服務商萬國數據(09698.HK)升4.2%。
其他科技股方面,美團(03690.HK)反彈1.7%報107元,京東(09618.HK)升0.4%。騰訊(00700.HK)跌1.7%報650元,快手(01024.HK)、網易(09999.HK)、嗶哩嗶哩(09626.HK)及小米(01810.HK)跌不足1%。東方甄選(01797.HK)升13.1%。丘鈦(01478.HK)出售印度丘鈦51.08%股權,料錄收益逾8.33億人民幣,丘鈦升4.9%。微盟(02013.HK)向無極資本折讓8.9%配股淨籌逾15億元,股價升5.2%。
車股方面,比亞迪(01211.HK)升2%,吉利(00175.HK)跌3.6%,智駕晶片股地平線(09660.HK)升6.8%。電池股寧德時代(03750.HK)升1.7%。消費股方面,中免(01880.HK)及泡泡瑪特(09992.HK)升5.3%及3.9%,國航(00753.HK)跌3.1%。醫藥股恆瑞(01276.HK)注射用瑞康曲妥珠單抗新適應症上市申請獲受理,慢性乙肝注射液被納入擬突破性治療品種,股價升5.4%。
金融股方面,匯控(00005.HK)升0.8%,港交所(00388.HK)及友邦(01299.HK)跌1.3%及0.5%。富衛(01828.HK)升4.9%,內險股財險(02328.HK)及人保(01339.HK)跌2.5%及3.2%。內房股下滑,萬科(02202.HK)、遠洋(03377.HK)、融創(01918.HK)、合景泰富(01813.HK)、富力(02777.HK)及雅居樂(03383.HK)跌4.3%至5.6%。施政報告未對樓市「派糖」,本地地產股長實集團(01113.HK)、恆地(00012.HK)及新地(00016.HK)跌不足1%,新世界(00017.HK)跌1.9%。
煤炭股中煤(01898.HK)及兗礦(01171.HK)各回吐逾3%。香港寬頻(01310.HK)股價飆升逾54%收7.91元,成交額16.4億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.